Диссертация (1154752), страница 23
Текст из файла (страница 23)
Adverse reactions to antibiotics in hospitalized Iranian children [Text] / G.T.Khotaei, F. Fattahi, Z. Pourpak [et al.] // J Microbiol Immunol Infect. – 2008. –Vol. 41, № 2. – P. 160–16487.Analysis of the direct cost of adverse drug reactions in hospitalised patients[Text] / R. Bordet, S. Gautier, H. Le Louet, B. Dupuis, J. Caron // Eur J ClinPharmacol. – 2001. – Vol. 56, № 12. – P. 935–94188.Awareness about and views of parents on the off-label drug use in children[Text] / V. Bang, A.
Mallad, S. Kannan, S.B. Bavdekar [et al.] // Int J Risk SafMed. – 2014. – Vol. 26, № 2. – P. 61–7089.Bandekar, M.S. Quality check of spontaneous adverse drug reaction reportingforms of different countries [Text] / M.S. Bandekar, S.R.Anwikar, N.A.Kshirsagar // Pharmacoepidemiol Drug Saf.
– 2010. – Vol. 19, № 11. – P. 1181–118590.Baniasadi, S. Developing an adverse drug reaction reporting system at a teachinghospital [Text] / S. Baniasadi, F. Fahimi, G. Shalviri // Basic Clin PharmacolToxicol. – 2008. – Vol. 102, № 4. – P. 408–41191. British National Formulary [Electronic resource]. – URL: https://www.bnf.org.– (accessed: 20.02.2017)92.Children Are Not Just Small Adults: The Urgent Need for High-Quality TrialEvidence in Children [Text] / P. T. Klassen, L.
Hartling, J.C. Craig, M. Offringa// PLoS Medicine. – 2008. – Vol. 5. – P. 1180–118293.Children's views on unlicensed/off-label paediatric prescribing and paediatricclinical trials [Text] / T. Mukattash, K. Trew, A.F. Hawwa [et al.] // Eur J ClinPharmacol. – 2012. – Vol.
68,№ 2. – P. 141–14813594.Choonara, I. Unlicensed and off-label drug use in children: implications forsafety [Text] / I. Choonara, S. Conroy // Drug Saf. – 2002. – Vol. 25, № 1. – P.1–595.Clavenna, A. Adverse drug reactions in childhood: a review of prospectivestudies and safety alerts [Text] / A. Clavenna, M. Bonati // Arch Dis Child. –2009.
– Vol. 94, № 9. – P. 724–72896.Clavenna, A. Drug prescriptions to outpatient children: a review of the literature[Text] / A. Clavenna, M. Bonati // Eur J Clin Pharmacol. – 2009. – Vol. 65, №8. – P. 749–75597.Cliff-Eribo, K.O. Systematic review of paediatric studies of adverse drugreactions from pharmacovigilance databases [Text] / K.O.
Cliff-Eribo, H.Sammons, I. Choonara // Expert Opin Drug Saf. – 2016. – Vol. 15, № 10. – P.1321–132898.Clinical setting influences off-label and unlicensed prescribing in a paediatricteaching hospital [Electronic resource] / P. Czarniak, L.
Bint, L. Favié [et al.] //PLoSOne.–2015.–Vol.10,№3.–URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4355417/pdf/pone.0120630.pdf.– (accessed: 28.12.2016)99.Clinical trials [Electronic resource] // EU Clinical Trials Register. – URL:https://www.clinicaltrialsregister.eu/ctr-search/search. – (accessed: 12.04.2017)100.Comparative Assessment of Off-label and Unlicensed Drug Prescriptionsin Children: FDA Versus ANSM Guidelines [Text] / S. Berdkan, L.Rabbaa, A.Hajj [et al.] // Clin Ther. – 2016. – Vol. 38, № 8.
– P. 1833–1844101.Comparison between paediatric and adult suspected adverse drug reactionsreported to the European medicines agency: implications for pharmacovigilance[Text] / K.V. Blake, C. Zaccaria, F. Domergue [et al.] // Paediatr Drugs. – 2014.– Vol. 16, №4. – P. 309–319.102.Consequences, measurement, and evaluation of the costs associated withadverse drug reactions among hospitalized patients in China [Electronicresource] / S. Qing-ping, J. Xiao-dong, D. Feng, L. Yan [et al.] // BMC Health136ServRes.–2014.–№14.–URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3931293/pdf/1472-6963-1473.pdf. – (accessed: 14.12.2016)103.Cuzzolin, L.
Off-label and unlicensed drug treatments in NeonatalIntensive Care Units: an Italian multicentre study [Text] / L. Cuzzolin, R.Agostino // Eur J Clin Pharmacol. – 2016. – Vol. 72, № 1. – P. 117–123104.Definition of Unlicensed Medicine [Electronic resource]. – URL:http://medical-dictionary.thefreedictionary.com/Unlicensed+Medicine.–(accessed: 21.02.2017)105.Diagnosis and management of drug hypersensitivity reactions [Text] / A.Romano, M.J. Torres, M. Castells [et al.] // J Allergy Clin Immunol. – 2011. –Vol. 127, Suppl. 3. – P. 67–73106.Dos Santos, L.
Drug utilization study in pediatric prescriptions of auniversity hospital in southern Brazil: off-label, unlicensed and high-alertmedications [Text] / L. Dos Santos, I. Heineck // Farm Hosp. – 2012. – Vol. 36,№ 4. – P. 180–186107.Drug use in children: cohort study in tree European countries [Electronicresource] / M.
Sturkenboom, K. Verhamme, A. Nicolosi [et al.] // BMJ. – 2008.– Vol. 337. – URL: doi:10.1136/bmj.a2245. – (accessed: 28.12.2016)108.Drug use in French children: a population-based study [Text] /A. Bénard-Laribière, J. Jové, R. Lassalle [et al.] // Arch Dis Child.
2015. – Vol. 100, № 10.– P. 960–965109.Drug utilization pattern in children and off-label use of medicines in apediatric intensive care unit [Text] / E. Blanco-Reina, A.F. Medina-Claros, M.A.Vega-Jiménez [et al.] // Med Intensiva. – 2016. – Vol. 40, № 1. – P. 1–8110.Ellul, I.C. Paediatric off-label and unlicensed prescribing in primary care inMalta: Prospective observational drug utilisation study [Text] / I.C. Ellul, V.Grech, S.
Attard-Montalto // Int J Risk Saf Med. – 2015. – Vol. 27, № 3. – P.123–134137111.Elzagallaai, A.A. Adverse Drug Reactions in Children: The Double-EdgedSword of Therapeutics [Text] / A.A. Elzagallaa, M. Greff , M.J. Rieder // ClinPharmacol Ther. –2017. –Vol.101, № 6. – P.
725–735112.Emergency department visits for antibiotic-associated adverse events[Text] / N. Shehab, P.R. Patel, A. Srinivasan, D.S. Budnitz // Clin Infect Dis. –2008. – Vol. 47, № 6. – P. 735–743113.Essential medicines and health products. Pharmacovigilance [Electronicresource]//WorldHealthOrganization.–URL:http://www.who.int/medicines/areas/quality_safety/safety_efficacy/pharmvigi/en.– (accessed: 19.02.2017)EudraVigilance [Electronic resource] // European Medicines Agency. –114.URL:http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000679.jsp&mid=WC0b01ac05800250b5. – (accessed:21.02.2017)115.European Medicines Agency policy on access to EudraVigilance data formedicin al products for human use [Electronic resource] / Inspections, HumanMedicines Pharmacovigilance and Committees Division// European MedicinesAgency.–2016.–URL:http://www.ema.europa.eu/docs/en_GB/document_library/Other/2016/12/WC500218300.pdf.
– (accessed:21.02.2017)116.Glasgow, J.F. Reye syndrome – insights on causation and prognosis [Text]/ J.F. Glasgow, B. Middleton // Arch Dis Child. – 2001. – Vol. 85. – P. 351–353117.Goločorbin Kon, S. Reasons for and frequency of off-label drug use [Text]/ S. Goločorbin Kon, I. Iliković, M. Mikov // Med Pregl. – 2015. – Vol. 68, № 1–2. – P. 35–40118.Gonçalves, M.G. Frequency of prescriptions of off-label drugs and drugsnot approved for pediatric use in primary health care in a southern municipalityof Brazil [Text] / M.G. Gonçalves, I.Heineck // Rev Paul Pediatr. – 2016.
–Vol. 34, №1. – P. 11–17138119.Good practice in prescribing and managing medicines and devices[Electronicresource]//GeneralMedicalCouncil.–2013.URL:http://www.gmc-uk.org/Prescribing_guidance.pdf_59055247.pdf.––(accessed: 17.02.2017)120.Guidanceforindustry.Goodpharmacovigilancepracticesandpharmacoepidemiologic Assessment [Electronic resource] / U.S.
Department ofHealth and Human Services Food and Drug Administration, Center for DrugEvaluation and Research, Center for Biologics Evaluation and Research // FoodandDrugAdministration.–2005.–https://www.fda.gov/OHRMS/DOCKETS/98fr/04d-0189-gdl0002.pdf.URL:–(accessed: 22.02.2017)121.Guideline on good pharmacovigilance practices (GVP). Module VI –Management and reporting of adverse reactions to medicinal products (Rev 1)[Electronic resource] // European Medicines Agency, Heads of Medicines–Agencies.2014.–URL:http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/09/WC500172402.pdf. – (accessed: 20.02.2014)122.Guidelines for ATC classification and DDD assignment 2017 [Electronicresource] // WHO Collaborating Centre for Drug Statistics Methodology.
––2016.URL:https://www.whocc.no/filearchive/publications/2017_guidelines_web.pdf.–(accessed: 28.02.2017)123.High prevalence of off-label and unlicensed drug prescribing in a Brazilianintensive care unit [Text] / A. Ferreira Lde, C. Ibiapina Cda, M.G. Machado,E.D. Fagundes // Rev Assoc Med Bras (1992). – 2012. – Vol. 58, № 1. – P. 82–87124.How to promote adverse drug reaction reports using information systems -a systematic review and meta-analysis [Electronic resource] / I.
Ribeiro-Vaz,A.M. Silva, C. Costa Santos, R. Cruz-Correia // BMC Med Inform Decis Mak. –2016.–№16.–URL:139https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4772685/pdf/12911_2016_Article_265.pdf. – (accessed: 17.09.16)125.Incidence and costs of adverse drug reactions in a tertiary care pediatricintensive care unit [Text] / W. Du, V. Tutag Lehr, M. Caverly [et al.] // J ClinPharmacol. – 2013. – Vol. 53, № 5. – P.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
